Exhibit 99

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

Forward-Looking Statements

Certain statements contained in this press release and the accompanying tables are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "hope," "anticipate," "plan" and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These statements are based on current expectations and assumptions and involve various risks and uncertainties, which could cause Chemed's actual results to differ from those expressed in such forward-looking statements.

These risks and uncertainties arise from, among other things, possible changes in regulations governing the hospice care or plumbing and drain cleaning industries; periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs; difficulties predicting patient length of stay and estimating potential Medicare reimbursement obligations; challenges inherent in Chemed's growth strategy; the current shortage of qualified nurses, other healthcare professionals and licensed plumbing and drain cleaning technicians; Chemed’s dependence on patient referral sources; and other factors detailed under the caption "Description of Business by Segment" or "Risk Factors" in Chemed’s most recent report on form 10-Q or 10-K and its other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on such forward-looking statements and there are no assurances that the matters contained in such statements will be achieved.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)(unaudited)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Service revenues and sales	$	606,181	$	564,532	$	1,791,294	$	1,678,505
Cost of services provided and goods sold		396,187		362,358		1,171,064		1,107,256
Selling, general and administrative expenses (aa)		101,981		99,602		320,109		294,684
Depreciation		13,147		12,858		39,601		37,778
Amortization		2,550		2,521		7,617		7,548
Other operating expense		159		343		288		2,064
Total costs and expenses		514,024		477,682		1,538,679		1,449,330
Income from operations		92,157		86,850		252,615		229,175
Interest expense		(427)		(444)		(1,281)		(2,766)
Other income--net (bb)		9,299		6,859		28,008		8,365
Income before income taxes		101,029		93,265		279,342		234,774
Income taxes		(25,253)		(18,307)		(67,662)		(52,318)
Net income	$	75,776	$	74,958	$	211,680	$	182,456
Earnings Per Share
Net income	$	5.04	$	4.97	$	14.04	$	12.14
Average number of shares outstanding		15,025		15,075		15,082		15,034
Diluted Earnings Per Share
Net income	$	5.00	$	4.93	$	13.88	$	12.02
Average number of shares outstanding		15,168		15,200		15,253		15,178

(aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
SG&A expenses before long-term incentive compensation
and the impact of market value adjustments related to
deferred compensation plans	$	93,269	$	91,792	$	287,712	$	281,426
Market value adjustments related to deferred
compensation trusts		5,629		4,257		16,600		5,441
Long-term incentive compensation		3,083		3,553		15,797		7,817
Total SG&A expenses	$	101,981	$	99,602	$	320,109	$	294,684

(bb) Other income--net comprises (in thousands):
	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Market value adjustments related to deferred
compensation trusts	$	5,629	$	4,257	$	16,600	$	5,441
Interest income		3,668		2,600		11,405		2,863
Other		2		2		3		61
Total other income--net	$	9,299	$	6,859	$	28,008	$	8,365


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)(unaudited)

	September 30,
	2024		2023
Assets
Current assets
Cash and cash equivalents	$	238,451	$	173,150
Accounts receivable less allowances		196,481		168,031
Inventories		9,899		12,511
Prepaid income taxes		14,229		11,337
Prepaid expenses		31,377		29,510
Total current assets		490,437		394,539
Investments of deferred compensation plans held in trust		126,631		104,410
Properties and equipment, at cost less accumulated depreciation		200,939		205,462
Lease right of use asset		134,111		123,353
Identifiable intangible assets less accumulated amortization		94,753		92,768
Goodwill		666,860		584,977
Other assets		55,704		56,570
Total Assets	$	1,769,435	$	1,562,079
Liabilities
Current liabilities
Accounts payable	$	44,938	$	56,508
Accrued insurance		60,308		61,122
Accrued income taxes		3,385		5,135
Accrued compensation		73,141		74,865
Short-term lease liability		42,490		37,615
Other current liabilities		40,517		61,974
Total current liabilities		264,779		297,219
Deferred income taxes		28,076		30,381
Deferred compensation liabilities		122,240		102,815
Long-term lease liability		105,416		99,346
Other liabilities		13,169		13,075
Total Liabilities		533,680		542,836
Stockholders' Equity
Capital stock		37,395		37,013
Paid-in capital		1,462,569		1,254,356
Retained earnings		2,639,011		2,362,928
Treasury stock, at cost		(2,905,430)		(2,637,102)
Deferred compensation payable in Company stock		2,210		2,048
Total Stockholders' Equity		1,235,755		1,019,243
Total Liabilities and Stockholders' Equity	$	1,769,435	$	1,562,079


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)(unaudited)

	Nine Months Ended September 30,
	2024		2023
Cash Flows from Operating Activities
Net income	$	211,680	$	182,456
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization		47,218		45,326
Stock option expense		23,933		22,376
Noncash long-term incentive compensation		15,783		6,637
Litigation settlements		(5,750)		2,050
Benefit for deferred income taxes		(2,245)		(8,232)
Noncash directors' compensation		1,282		1,444
Amortization of debt issuance costs		241		500
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations:
Increase in accounts receivable		(14,336)		(27,843)
Decrease/(increase) in inventories		2,125		(2,239)
(Increase)/decrease in prepaid expenses		(1,173)		781
Decrease in accounts payable and
other current liabilities		(19,641)		(15,815)
Change in current income taxes		(4,545)		12,314
Net change in lease assets and liabilities		(400)		(892)
Increase in other assets		(21,101)		(8,622)
Increase in other liabilities		18,348		11,426
Other sources		1,165		69
Net cash provided by operating activities		252,584		221,736
Cash Flows from Investing Activities
Business combinations, net of cash acquired		(97,400)		(3,994)
Capital expenditures		(36,770)		(45,075)
Proceeds from sale of fixed assets		3,060		506
Other uses		(281)		(409)
Net cash used by investing activities		(131,391)		(48,972)
Cash Flows from Financing Activities
Purchases of treasury stock		(152,049)		(27,769)
Proceeds from exercise of stock options		49,906		58,277
Dividends paid		(19,594)		(17,446)
Change in cash overdrafts payable		(15,749)		16,182
Capital stock surrendered to pay taxes on stock-based compensation		(8,827)		(5,446)
Payments on long-term debt		-		(97,500)
Other uses		(387)		(38)
Net cash used by financing activities		(146,700)		(73,740)
(Decrease)/increase in Cash and Cash Equivalents		(25,507)		99,024
Cash and cash equivalents at beginning of year		263,958		74,126
Cash and cash equivalents at end of year	$	238,451	$	173,150


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(in thousands)(unaudited)
							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2024 (a)
Service revenues and sales	$	391,406	$	214,775	$	-	$	606,181
Cost of services provided and goods sold		294,936		101,251		-		396,187
Selling, general and administrative expenses		25,883		57,072		19,026		101,981
Depreciation		5,063		8,071		13		13,147
Amortization		26		2,524		-		2,550
Other operating expense		97		62		-		159
Total costs and expenses		326,005		168,980		19,039		514,024
Income/(loss) from operations		65,401		45,795		(19,039)		92,157
Interest expense		(46)		(114)		(267)		(427)
Intercompany interest income/(expense)		4,920		3,656		(8,576)		-
Other income—net		62		18		9,219		9,299
Income/(loss) before income taxes		70,337		49,355		(18,663)		101,029
Income taxes		(16,851)		(11,400)		2,998		(25,253)
Net income/(loss)	$	53,486	$	37,955	$	(15,665)	$	75,776

2023 (b)
Service revenues and sales	$	333,728	$	230,804	$	-	$	564,532
Cost of services provided and goods sold		253,731		108,627		-		362,358
Selling, general and administrative expenses		25,256		55,141		19,205		99,602
Depreciation		5,009		7,836		13		12,858
Amortization		26		2,495		-		2,521
Other operating expense/(income)		(53)		396		-		343
Total costs and expenses		283,969		174,495		19,218		477,682
Income/(loss) from operations		49,759		56,309		(19,218)		86,850
Interest expense		(52)		(131)		(261)		(444)
Intercompany interest income/(expense)		4,935		3,040		(7,975)		-
Other income—net		849		34		5,976		6,859
Income/(loss) before income taxes		55,491		59,252		(21,478)		93,265
Income taxes		(11,160)		(8,925)		1,778		(18,307)
Net income/(loss)	$	44,331	$	50,327	$	(19,700)	$	74,958


The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(in thousands)(unaudited)

							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2024 (a)
Service revenues and sales	$	1,119,970	$	671,324	$	-	$	1,791,294
Cost of services provided and goods sold		852,347		318,717		-		1,171,064
Selling, general and administrative expenses		73,968		175,683		70,458		320,109
Depreciation		15,288		24,275		38		39,601
Amortization		79		7,538		-		7,617
Other operating expense		160		128		-		288
Total costs and expenses		941,842		526,341		70,496		1,538,679
Income/(loss) from operations		178,128		144,983		(70,496)		252,615
Interest expense		(138)		(349)		(794)		(1,281)
Intercompany interest income/(expense)		15,096		10,638		(25,734)		-
Other income—net		138		64		27,806		28,008
Income/(loss) before income taxes		193,224		155,336		(69,218)		279,342
Income taxes		(46,517)		(36,010)		14,865		(67,662)
Net income/(loss)	$	146,707	$	119,326	$	(54,353)	$	211,680

2023 (b)
Service revenues and sales	$	965,066	$	713,439	$	-	$	1,678,505
Cost of services provided and goods sold		770,470		336,786		-		1,107,256
Selling, general and administrative expenses		71,248		171,966		51,470		294,684
Depreciation		14,907		22,830		41		37,778
Amortization		78		7,470		-		7,548
Other operating expense/(income)		(15)		2,079		-		2,064
Total costs and expenses		856,688		541,131		51,511		1,449,330
Income/(loss) from operations		108,378		172,308		(51,511)		229,175
Interest expense		(154)		(387)		(2,225)		(2,766)
Intercompany interest income/(expense)		14,393		8,652		(23,045)		-
Other income—net		1,109		96		7,160		8,365
Income/(loss) before income taxes		123,726		180,669		(69,621)		234,774
Income taxes		(28,503)		(38,315)		14,500		(52,318)
Net income/(loss)	$	95,223	$	142,354	$	(55,121)	$	182,456


The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(in thousands)(unaudited)
							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2024
Net income/(loss)	$	53,486	$	37,955	$	(15,665)	$	75,776
Add/(deduct):
Interest expense		46		114		267		427
Income taxes		16,851		11,400		(2,998)		25,253
Depreciation		5,063		8,071		13		13,147
Amortization		26		2,524		-		2,550
EBITDA		75,472		60,064		(18,383)		117,153
Add/(deduct):
Intercompany interest expense/(income)		(4,920)		(3,656)		8,576		-
Interest income		(59)		(18)		(3,589)		(3,666)
Stock option expense		-		-		6,038		6,038
Long-term incentive compensation		-		-		3,083		3,083
Acquisition expense		394		(8)		-		386
Adjusted EBITDA	$	70,887	$	56,382	$	(4,275)	$	122,994

2023
Net income/(loss)	$	44,331	$	50,327	$	(19,700)	$	74,958
Add/(deduct):
Interest expense		52		131		261		444
Income taxes		11,160		8,925		(1,778)		18,307
Depreciation		5,009		7,836		13		12,858
Amortization		26		2,495		-		2,521
EBITDA		60,578		69,714		(21,204)		109,088
Add/(deduct):
Intercompany interest expense/(income)		(4,935)		(3,040)		7,975		-
Interest income		(847)		(34)		(1,719)		(2,600)
Litigation settlement		-		300		-		300
Stock option expense		-		-		5,495		5,495
Long-term incentive compensation		-		-		3,553		3,553
Adjusted EBITDA	$	54,796	$	66,940	$	(5,900)	$	115,836

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(in thousands)(unaudited)
							Chemed
	VITAS		Roto-Rooter		Corporate		Consolidated
2024
Net income/(loss)	$	146,707	$	119,326	$	(54,353)	$	211,680
Add/(deduct):
Interest expense		138		349		794		1,281
Income taxes		46,517		36,010		(14,865)		67,662
Depreciation		15,288		24,275		38		39,601
Amortization		79		7,538		-		7,617
EBITDA		208,729		187,498		(68,386)		327,841
Add/(deduct):
Intercompany interest expense/(income)		(15,096)		(10,638)		25,734		-
Interest income		(136)		(64)		(11,205)		(11,405)
Stock option expense		-		-		23,933		23,933
Long-term incentive compensation		-		-		10,460		10,460
Severance arrangement		-		-		5,337		5,337
Acquisition expense		1,302		37		-		1,339
Adjusted EBITDA	$	194,799	$	176,833	$	(14,127)	$	357,505
2023
Net income/(loss)	$	95,223	$	142,354	$	(55,121)	$	182,456
Add/(deduct):
Interest expense		154		387		2,225		2,766
Income taxes		28,503		38,315		(14,500)		52,318
Depreciation		14,907		22,830		41		37,778
Amortization		78		7,470		-		7,548
EBITDA		138,865		211,356		(67,355)		282,866
Add/(deduct):
Intercompany interest expense/(income)		(14,393)		(8,652)		23,045		-
Interest income		(1,046)		(96)		(1,720)		(2,862)
Stock option expense		-		-		22,376		22,376
Long-term incentive compensation		-		-		7,817		7,817
Litigation settlements		-		2,056		-		2,056
Adjusted EBITDA	$	123,426	$	204,664	$	(15,837)	$	312,253

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net income as reported	$	75,776	$	74,958	$	211,680	$	182,456
Add/(deduct) pre-tax cost of:
Stock option expense		6,038		5,495		23,933		22,376
Long-term incentive compensation		3,083		3,553		10,460		7,817
Amortization of reacquired franchise rights		2,352		2,352		7,056		7,056
Severance arrangement		-		-		5,337		-
Acquisition expense		386		-		1,339		-
Litigation settlement		-		300		-		2,056
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1)		(1,761)		(1,326)		(6,762)		(6,443)
Tax impact of deferred tax rate change		-		(4,241)		-		(4,241)
Excess tax benefits on stock compensation		(389)		(225)		(4,308)		(3,376)
Adjusted net income	$	85,485	$	80,866	$	248,735	$	207,701

Diluted Earnings Per Share As Reported
Net income	$	5.00	$	4.93	$	13.88	$	12.02
Average number of shares outstanding		15,168		15,200		15,253		15,178

Adjusted Diluted Earnings Per Share
Adjusted net income	$	5.64	$	5.32	$	16.31	$	13.68
Average number of shares outstanding		15,168		15,200		15,253		15,178

(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
OPERATING STATISTICS	2024			2023			2024			2023
Net revenue ($000) (c)
Homecare	$	338,344		$	287,389		$	967,981		$	832,554
Inpatient		29,923			27,818			89,297			84,312
Continuous care		25,799			22,032			74,295			63,054
Other		5,082			3,562			13,900			9,738
Subtotal	$	399,148		$	340,801		$	1,145,473		$	989,658
Room and board, net		(3,336)			(2,646)			(9,437)			(8,317)
Contractual allowances		(2,167)			(4,302)			(10,077)			(10,650)
Medicare cap allowance		(2,239)			(125)			(5,989)			(5,625)
Net Revenue	$	391,406		$	333,728		$	1,119,970		$	965,066
Net revenue as a percent of total before Medicare cap allowance
Homecare		84.8	%		84.3	%		84.5	%		84.1	%
Inpatient		7.5			8.2			7.8			8.5
Continuous care		6.5			6.5			6.5			6.4
Other		1.2			1.0			1.2			1.0
Subtotal		100.0			100.0			100.0			100.0
Room and board, net		(0.8)			(0.8)			(0.8)			(0.8)
Contractual allowances		(0.5)			(1.3)			(0.9)			(1.1)
Medicare cap allowance		(0.6)			-			(0.5)			(0.6)
Net Revenue		98.1	%		97.9	%		97.8	%		97.5	%
Days of care
Homecare		1,622,680			1,391,377			4,621,755			4,018,469
Nursing home		320,664			287,785			908,013			833,112
Respite		9,952			7,292			26,806			19,211
Subtotal routine homecare and respite		1,953,296			1,686,454			5,556,574			4,870,792
Inpatient		26,524			25,493			79,064			76,987
Continuous care		24,365			23,071			72,335			65,630
Total		2,004,185			1,735,018			5,707,973			5,013,409

Number of days in relevant time period		92			92			274			273
Average daily census ("ADC") (days)
Homecare		17,639			15,124			16,867			14,720
Nursing home		3,485			3,128			3,314			3,052
Respite		108			79			98			70
Subtotal routine homecare and respite		21,232			18,331			20,279			17,842
Inpatient		288			277			289			282
Continuous care		265			251			264			240
Total		21,785			18,859			20,832			18,364

Total Admissions		16,775			15,774			51,020			47,564
Total Discharges		16,217			15,328			48,285			45,837
Average length of stay (days)		102.0			103.1			102.2			100.8
Median length of stay (days)		18.0			17.0			17.0			16.0

ADC by major diagnosis
Cerebro		43.6	%		42.0	%		43.7	%		42.2	%
Neurological		13.3			14.7			13.3			15.9
Cancer		10.0			10.6			10.0			10.6
Cardio		16.3			16.4			16.2			16.1
Respiratory		7.1			7.2			7.2			7.1
Other		9.7			9.1			9.6			8.1
Total		100.0	%		100.0	%		100.0	%		100.0	%
Admissions by major diagnosis
Cerebro		28.4	%		26.6	%		27.7	%		26.3	%
Neurological		7.7			8.8			7.9			9.9
Cancer		25.7			26.1			25.1			26.0
Cardio		15.1			16.0			15.7			16.2
Respiratory		9.5			9.7			9.9			10.1
Other		13.6			12.8			13.7			11.5
Total		100.0	%		100.0	%		100.0	%		100.0	%

Estimated uncollectible accounts as a percent of revenues		0.6	%		1.3	%		0.9	%		1.1	%

Accounts receivable --
Days of revenue outstanding-excluding unapplied Medicare payments		37.5			36.4			n.a.			n.a.
Days of revenue outstanding-including unapplied Medicare payments		35.5			33.8			n.a.			n.a.

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(unaudited)

(a)	Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing operations
	(in thousands):
		Three Months Ended September 30, 2024
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(6,038)	$	(6,038)
	Long-term incentive compensation		-		-		(3,083)		(3,083)
	Amortization of reacquired franchise agreements		-		(2,352)		-		(2,352)
	Acquisition expense		(394)		8		-		(386)
	Pretax impact on earnings		(394)		(2,344)		(9,121)		(11,859)
	Excess tax benefits on stock compensation		-		-		389		389
	Income tax benefit on the above		96		546		1,119		1,761
	After-tax impact on earnings	$	(298)	$	(1,798)	$	(7,613)	$	(9,709)

		Nine Months Ended September 30, 2024
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(23,933)	$	(23,933)
	Long-term incentive compensation		-		-		(10,460)		(10,460)
	Amortization of reacquired franchise agreements		-		(7,056)		-		(7,056)
	Severance arrangement		-		-		(5,337)		(5,337)
	Acquisition expense		(1,302)		(37)		-		(1,339)
	Pretax impact on earnings		(1,302)		(7,093)		(39,730)		(48,125)
	Excess tax benefits on stock compensation		-		-		4,308		4,308
	Income tax benefit on the above		317		1,652		4,793		6,762
	After-tax impact on earnings	$	(985)	$	(5,441)	$	(30,629)	$	(37,055)

(b)	Included in the results of operations for 2023 are the following significant credits/(charges) which may not be indicative of ongoing operations
	(in thousands):
		Three Months Ended September 30, 2023
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(5,495)	$	(5,495)
	Long-term incentive compensation		-		-		(3,553)		(3,553)
	Amortization of reacquired franchise agreements		-		(2,352)		-		(2,352)
	Litigation settlement		-		(300)		-		(300)
	Pretax impact on earnings		-		(2,652)		(9,048)		(11,700)
	Excess tax benefits on stock compensation		-		-		225		225
	Tax impact of deferred tax rate change		1,772		3,559		(1,090)		4,241
	Income tax benefit on the above		-		412		914		1,326
	After-tax impact on earnings	$	1,772	$	1,319	$	(8,999)	$	(5,908)

		Nine Months Ended September 30, 2023
		VITAS		Roto-Rooter		Corporate		Consolidated

	Stock option expense	$	-	$	-	$	(22,376)	$	(22,376)
	Long-term incentive compensation		-		-		(7,817)		(7,817)
	Amortization of reacquired franchise agreements		-		(7,056)		-		(7,056)
	Litigation settlements		-		(2,056)		-		(2,056)
	Pretax impact on earnings		-		(9,112)		(30,193)		(39,305)
	Excess tax benefits on stock compensation		-		-		3,376		3,376
	Tax impact of deferred tax rate change		1,772		3,559		(1,090)		4,241
	Income tax benefit on the above		-		2,123		4,320		6,443
	After-tax impact on earnings	$	1,772	$	(3,430)	$	(23,587)	$	(25,245)

(c)

VITAS has 10 large (greater than 450 ADC), 23 medium (greater than 200 but less than 450 ADC) and 22 small (less than 200 ADC) hospice programs. Of Vitas' 32 Medicare provider numbers, for the trailing 12 months, 24 provider numbers have a Medicare cap cushion of greater than 10%, one provider number has a Medicare cap cushion between 5% and 10%, four provider numbers have a Medicare cap cushion between 0% and 5%, and three provider numbers have a Medicare cap liability.